2,3 Efficacy findings from the KEYNOTE-868/NRG- GY018 trial (NCT03914612) led to the FDA’s approval of pembrolizumab for endometrial carcinoma. The trial stratified 222 patients to the MMR- deficient ...
MSD acquired the therapy from Acceleron Pharma. Credit: Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. MSD has received ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Merck will discontinue its antibody-drug Zinplava for a bacterial infection that can lead to fatal diarrhea, according to the U.S. Food and Drug Administration's website. Zinplava, first approved by ...
MSD has already reported data from its pivotal NRG-GY018 study of Keytruda (pembrolizumab), which showed a similar 70% reduction in a dMMR population, but so far, there's no word on a regulatory ...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial ...
RAHWAY, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the Phase 3 MOVe-NOW clinical trial to evaluate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback